XML 23 R9.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Supplemental Balance Sheet and Cash Flow Information | 12 Months Ended
--- | ---
Jun. 30, 2022
Notes to Financial Statements |
Supplemental Balance Sheet Disclosures [Text Block] | Note 3. Supplemental Balance Sheet and Cash Flow Information: Inventories: Inventories consist of (in thousands):
​ | ​ | ​ | ​ | ​ | ​
​ | June 30,
​ | 2022 |  | 2021
​ | ​ | ​ | ​ | ​ | ​
Raw materials | $ | 79,291 | ​ | $ | 55,096
Finished goods(1) |  | 66,943 | ​ |  | 67,108
Inventories, net | $ | 146,234 | ​ | $ | 122,204
(1) | Finished goods inventory of $5,111 and $5,456 is included within other long-term assets in the June 30, 2022 and June 30, 2021 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.
Property and Equipment: Property and equipment consist of (in thousands):
​ | ​ | ​ | ​ | ​ | ​
​ | June 30,
​ | 2022 |  | 2021
Cost: | ​ |  |  | ​ |
Land | $ | 8,572 | ​ | $ | 8,612
Buildings and improvements |  | 229,551 | ​ |  | 190,661
Machinery and equipment | ​ | 174,813 | ​ |  | 149,410
Construction in progress |  | 21,729 | ​ | ​ | 49,073
Property and equipment, cost |  | 434,665 | ​ |  | 397,756
Accumulated depreciation and amortization |  | (211,423) | ​ |  | (189,849)
Property and equipment, net | $ | 223,242 | ​ | $ | 207,907
​ Intangibles assets were comprised of the following (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Useful Life | ​ | June 30,
​ | ​ | (years) | ​ | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Developed technology |  | 9 - 15 | ​ | $ | 542,038 | ​ | $ | 552,160
Trade names |  | 2 - 20 | ​ |  | 146,457 | ​ |  | 147,640
Customer relationships |  | 7 - 16 | ​ |  | 225,882 | ​ |  | 232,493
Patents |  | 10 | ​ |  | 3,313 | ​ |  | 2,926
Other intangibles |  | 5 - 15 | ​ |  | 6,306 | ​ |  | 6,316
Definite-lived intangible assets | ​ | ​ | ​ |  | 923,996 | ​ |  | 941,535
Accumulated amortization | ​ | ​ | ​ |  | (415,174) | ​ |  | (348,267)
Definite-lived intangibles assets, net | ​ | ​ | ​ |  | 508,822 | ​ |  | 593,268
In process research and development | ​ | ​ | ​ |  | 22,700 | ​ |  | 22,700
Total intangible assets, net | ​ | ​ | ​ | $ | 531,522 | ​ | $ | 615,968
​ Changes to the carrying amount of net intangible assets consist of (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30,
​ | ​ | 2022 | ​ | 2021
​ | ​ | ​ | ​ | ​ | ​ | ​
Beginning balance | ​ | $ | 615,968 | ​ | $ | 516,545
Acquisitions | ​ |  | — | ​ |  | 153,311
Other additions | ​ |  | 293 | ​ |  | 5,912
Amortization expense | ​ |  | (74,147) | ​ |  | (64,940)
Currency translation | ​ | ​ | (2,029) | ​ | ​ | 5,140
Eminence impairment (1) | ​ |  | (8,563) | ​ |  | —
Ending balance | ​ | $ | 531,522 | ​ | $ | 615,968
(1) As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of fiscal 2022. ​ Amortization expense related to developed technologies included in cost of sales was $40.6 million, $36.5 million, and $34.5 million in fiscal 2022, 2021, and 2020, respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $33.5 million, $28.4 million, and $26.6 million, in fiscal 2022, 2021, and 2020 respectively. The estimated future amortization expense for intangible assets as of June 30, 2022, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows (in thousands): ​
​ | ​ | ​ | ​
2023 |  | $ | 71,366
2024 | ​ |  | 68,702
2025 | ​ |  | 65,266
2026 | ​ |  | 61,689
2027 | ​ |  | 51,771
Thereafter | ​ |  | 190,028
Total | ​ | $ | 508,822
​ ​ ​ Changes in goodwill by segment and in total consist of (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Diagnostics and |  | ​
​ | ​ | Protein Sciences | ​ | Genomics | ​ | Total
June 30, 2020 |  | $ | 373,081 |  | $ | 355,229 |  | $ | 728,310
Acquisitions (Note 4) | ​ |  | 7,848 | ​ |  | 94,970 | ​ |  | 102,818
Currency translation | ​ |  | 11,788 | ​ |  | 151 | ​ |  | 11,939
June 30, 2021 | ​ | $ | 392,717 | ​ | $ | 450,350 | ​ | $ | 843,067
Acquisitions(1) | ​ |  | — | ​ | ​ | (4,407) | ​ | ​ | (4,407)
Eminence impairment | ​ | ​ | (8,275) | ​ | ​ | — | ​ | ​ | (8,275)
Currency translation | ​ |  | (7,949) | ​ | ​ | (335) | ​ | ​ | (8,284)
June 30, 2022 | ​ | $ | 376,493 | ​ | $ | 445,608 | ​ | $ | 822,101
​ (1)As discussed in Note 4, there was an adjustment to the preliminary allocation of the Asuragen acquisition opening balance sheet during the measurement period. ​ Supplemental Cash Flow Information: Supplemental cash flow information was as follows (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Year Ended June 30,
​ |  | 2022 |  | 2021 |  | 2020
Income taxes paid | ​ | $ | 30,341 | ​ | $ | 20,952 | ​ | $ | 41,992
Interest paid | ​ |  | 11,027 | ​ |  | 13,576 | ​ |  | 18,615
Non-cash activities: | ​ |  | ​ | ​ |  |  | ​ |  |
Acquisition-related liabilities(1) | ​ |  | 20,400 | ​ |  | 23,600 | ​ |  | (2,105)
Other intangibles(2) | ​ |  | — | ​ |  | 4,000 | ​ |  | —
(1) | Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.
(2) | $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration